I-CORPS: Scalable Production of Polymeric Nanoparticles Encapsulating Hydrophobic Compounds

I-CORPS：封装疏水性化合物的聚合物纳米颗粒的可规模化生产

• 批准号: 1566113
• 负责人: Ying Liu
• 金额: $ 5万
• 依托单位: University of Illinois at Chicago
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-11-01 至 2017-04-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1566113&HistoricalAwards=false
• 关键词: CORPS; Scalable; Production; Polymeric; Nanoparticles

The goal of this NSF I-Corps activity is to systematically study technology transition and establish the commercial viability of the technology of scalable production of polymeric nanoparticles encapsulating hydrophobic compounds. One of the greatest advantages of polymeric nanoparticles is that they can carry hydrophobic compounds at much higher concentrations than the solubility of these compounds in aqueous solutions and yet, the encapsulation keeps the compounds from being exposed to physiological conditions until they reach their targets. However, it is challenging to generate large-scale polymeric nanoparticles with well-controlled physical, chemical, and pharmaceutical properties for biomedical applications. The product being proposed is a continuous, scalable process for generating polymeric nanoparticles by integrating flash nanoprecipitation with drying processes. The resulting nanoparticles can have high drug loading, high drug encapsulation efficiency, and narrw particle size distribution.The team will reach the goal of this I-Corps study through assessing product possibilities, potential markets, economics and business models. If successful, the technology of commercial scale production of polymeric nanoparticles with controlled properties will initiate a paradigm shift in the biopharmaceutical industry with realized potential for health benefits for society at large. Low dose and dose frequency, and reduced side effects of the hydrophobic compounds can be achieved by increasing drug bioavailability. Drug compounds demonstrated to have in vitro or ex vivo therapeutic efficacy but undeliverable or difficult to administer can be formulated and available for clinical applications of treating complex diseases. Reproducibly generating nanoparticles with controlled propertied can serve as a platform to study drug pharmacokinetics,functionality, and efficacy.

NSF I-Corps活性的目的是系统地研究技术过渡并确定封装疏水化合物的聚合物纳米颗粒的可扩展生产技术的商业生存能力。 聚合物纳米颗粒的最大优势之一是，它们可以携带疏水化合物的浓度要比这些化合物在水溶液中的溶解度高得多，但是，封装使化合物无法暴露于生理条件，直到达到目标。然而，生成具有生物医学应用的物理，化学和药物特性良好的大规模聚合物纳米颗粒是一项挑战。提出的产品是通过将闪光灯纳米沉淀与干燥过程整合在一起的连续，可扩展的过程，用于生成聚合物纳米颗粒。由此产生的纳米颗粒可以具有很高的药物负载，高药物封装效率和纳尔沃粒度分布。该团队将通过评估产品可能性，潜在市场，经济学和商业模型来实现这项I-Corps研究的目标。如果成功的话，具有控制性能的聚合物纳米颗粒的商业规模生产技术将引发生物制药行业的范式转变，并具有实现的整个社会健康益处的潜力。低剂量和剂量频率以及疏水化合物的副作用降低，可以通过增加药物生物利用度来实现。可以制定药物化合物，具有体外或实体治疗疗效，但可以配制不可交付或难以给药，可用于治疗复杂疾病的临床应用。具有受控性能的可重复产生的纳米颗粒可以作为研究药代动力学，功能和功效的平台。